TimesSquare Capital Management LLC grew its position in shares of Merus (NASDAQ:MRUS - Free Report) by 49.5% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 272,435 shares of the biotechnology company's stock after purchasing an additional 90,215 shares during the period. TimesSquare Capital Management LLC owned approximately 0.40% of Merus worth $13,611,000 at the end of the most recent quarter.
Several other institutional investors have also recently made changes to their positions in MRUS. Allspring Global Investments Holdings LLC bought a new stake in Merus during the first quarter valued at approximately $72,000. nVerses Capital LLC raised its holdings in shares of Merus by 750.0% during the 3rd quarter. nVerses Capital LLC now owns 1,700 shares of the biotechnology company's stock valued at $85,000 after buying an additional 1,500 shares in the last quarter. US Bancorp DE bought a new stake in Merus in the 3rd quarter worth approximately $103,000. SG Americas Securities LLC purchased a new stake in Merus in the first quarter worth approximately $108,000. Finally, Mirae Asset Global Investments Co. Ltd. grew its position in Merus by 24.7% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,467 shares of the biotechnology company's stock valued at $118,000 after acquiring an additional 489 shares during the last quarter. Institutional investors own 96.14% of the company's stock.
Analyst Ratings Changes
A number of equities research analysts have recently issued reports on the stock. Canaccord Genuity Group raised shares of Merus to a "strong-buy" rating in a research note on Thursday, July 25th. Guggenheim raised their price objective on Merus from $93.00 to $111.00 and gave the company a "buy" rating in a research note on Tuesday, October 1st. Lifesci Capital upgraded Merus to a "strong-buy" rating in a report on Monday, July 29th. HC Wainwright reissued a "buy" rating and set a $85.00 price objective on shares of Merus in a research note on Friday, November 1st. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $85.00 target price on shares of Merus in a research note on Friday, November 1st. One investment analyst has rated the stock with a sell rating, eleven have assigned a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Buy" and a consensus target price of $86.70.
View Our Latest Research Report on Merus
Merus Trading Down 2.8 %
Merus stock traded down $1.54 during midday trading on Monday, hitting $52.96. The stock had a trading volume of 385,116 shares, compared to its average volume of 686,699. Merus has a 52-week low of $22.01 and a 52-week high of $61.61. The company has a market capitalization of $3.63 billion, a PE ratio of -13.41 and a beta of 1.12. The firm's fifty day moving average is $51.03 and its two-hundred day moving average is $51.86.
Merus (NASDAQ:MRUS - Get Free Report) last posted its earnings results on Thursday, October 31st. The biotechnology company reported ($0.95) EPS for the quarter, missing analysts' consensus estimates of ($0.90) by ($0.05). The firm had revenue of $11.77 million for the quarter, compared to the consensus estimate of $9.11 million. Merus had a negative net margin of 680.61% and a negative return on equity of 38.89%. As a group, equities research analysts predict that Merus will post -3.88 earnings per share for the current fiscal year.
Merus Company Profile
(
Free Report)
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.
Read More
Before you consider Merus, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merus wasn't on the list.
While Merus currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
